2. Signaling Pathways
  3. GPCR/G Protein
  4. Formyl Peptide Receptor (FPR)

Formyl Peptide Receptor (FPR)

Formyl peptide receptors (FPRs) are a group of G protein-coupled chemoattractant receptors, including FPR1, FPR2 and FPR3. FPR1 and FPR2 are expressed in both monocytes and neutrophils, while FPR3 is found in monocytes but not neutrophils. Besides myeloid cells, FPR1 is expressed in astrocytes, microglial cells, hepatocytes and immature dendritic cells. FPR2 shows an even wider distribution pattern than FPR1 and is expressed in a variety of non-myeloid cells including astrocytoma cells, epithelial cells, hepatocytes, microvascular endothelial cells, neuroblastoma cells, in addition to phagocytic leukocytes. FPRs are classified as Pathogen Recognition Receptors (PRRs) located on immune cells that play a key role in innate immunity due to their ability to recognize both, pathogen associated and damage-associated molecular patterns (PAMPs and DAMPs). FPRs participate not only in host defense and regulation of inflammatory response but also in the migration, proliferation, superoxide production and in several physio-pathological processes due to their unique binding properties and interaction with structurally diverse ligands.

Formyl Peptide Receptor (FPR) Related Products (33):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1119
    WRW4
    		99.99%
    WRW4, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC50 of 0.23 μM. WRW4 specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide.
    WRW4
  • HY-P1122
    Cyclosporin H
    		99.43%
    Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.
    Cyclosporin H
  • HY-101283
    HCH6-1
    		99.14%
    HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases.
    HCH6-1
  • HY-131180
    BMS-986235
    		99.48%
    BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure.
    BMS-986235
  • HY-103473A
    Boc-MLF TFA
    		99.69%
    Boc-MLF (TFA) is a peptide, used as a specific formyl peptide receptor (FPR) antagonist, also inhibits the signaling through formyl peptide receptor like 1 (FPRL1) at higher concentrations.
    Boc-MLF TFA
  • HY-P10724
    fMIFL
    		Agonist
    fMIFL is an FPR1 agonist. fMIFL can activate several signaling pathways responsible for various neutrophil functions, such as adhesion, chemotaxis, secretion of granule exocytosis, and the production of superoxide anions. fMIFL can be used in research on bacterial infections and tissue damage.
    fMIFL
  • HY-159583
    FPR2 agonist 4
    		Agonist
    FPR2 agonist 4 (compound 20) is a selective agonist of FPR2 with an EC50 of 0.2 nM.
    FPR2 agonist 4
  • HY-P10432
    SHAAGtide
    		Activator
    SHAAGtide is a FPRL1 activator. SHAAGtide has anti-inflammatory activity, mediates its biological activity via FPR2 and is used to reduce the expression of inflammatory cytokines in mouse models. SHAAGtide can be used in the study of diseases such as lung inflammation and fibrosis.
    SHAAGtide
  • HY-P1120
    WKYMVm
    		99.88%
    WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. In addition, WKYMVm is involved in the regulation of immune cells by activating FPRs, and WKYMVm can promote the chemotactic migration of immune cells and regulate the number and maturation of immune cells.
    WKYMVm
  • HY-P1795
    N-Boc-Phe-Leu-Phe-Leu-Phe
    		98.05%
    N-Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a formyl peptide receptor 1 (FPR1) antagonist, which increases pain effects and inhibits antinociceptive activity of annexin.
    N-Boc-Phe-Leu-Phe-Leu-Phe
  • HY-124071
    ACT-389949
    		99.96%
    ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders.
    ACT-389949
  • HY-P1121A
    WKYMVM-NH2 TFA
    		99.16%
    WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase.
    WKYMVM-NH2 TFA
  • HY-P2355
    {Boc}-Phe-Leu-Phe-Leu-Phe
    		99.50%
    {Boc}-Phe-Leu-Phe-Leu-Phe ({Boc}-FLFLF) is a formyl peptide receptor (FPR) family antagonist that preferentially inhibits activity triggered through the formyl peptide receptor.
    {Boc}-Phe-Leu-Phe-Leu-Phe
  • HY-19574
    FPR Agonist 43
    		99.79%
    FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist.
    FPR Agonist 43
  • HY-128113
    AG-09/1
    		99.79%
    AG-09/1 is a specific formyl peptide receptor 1 (FPR1) agonist. N-formyl peptide receptors (FPR) are important in host defense.
    AG-09/1
  • HY-156293
    FPR1 antagonist 1
    		Antagonist
    FPR1 antagonist 1 (compound 24a) is a formyl peptide receptor 1 (FPR1) antagonist with an IC50 of 25 nM. FPR1 antagonist 1 inhibits cell growth through a combined effect on cell proliferation and apoptosis and reduces cell migration, while inducing an increase in angiogenesis.
    FPR1 antagonist 1
  • HY-P1744
    N-Formyl-Met-Leu-Phe-Lys
    		98.98%
    N-Formyl-Met-Leu-Phe-Lys (fMLFK) is a peptide, acts as a potent and selective agonist of FPR1, with EC50s of 3.5 nM, 6.7 μM and 0.88 μM for FPR1, FPR2 and FPR2-D2817.32G, respectively.
    N-Formyl-Met-Leu-Phe-Lys
  • HY-144604
    FPR2 agonist 2
    		Agonist 99.59%
    FPR2 agonist 2 is a potent and permeates the blood?brain barrier FPR2 agonist with an EC50 of 0.13 μM, 1.1 μM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity.
    FPR2 agonist 2
  • HY-P1591
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys
    		98.86%
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA (For-Nle-Leu-Phe-Nle-Tyr-Lys-OH TFA) is a formyl peptide receptor (FPR) agonist.
    N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys
  • HY-P1118
    Ac9-25
    		98.54%
    Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR.
    Ac9-25